Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 75 /hr

★★★★★

☆☆☆☆☆

Hire Vaishnavi S.

United States

USD 75 /hr

Ph.D. Medical Writer Consultant | Expert in Solid Tumor Oncology | Renowned Scientist with 10+ yrs of experience

Profile Summary

Results-oriented and accomplished Ph.D. Medical Writer Consultant, Vaishnavi Sambandam, combines a decade of scientific leadership in prestigious institutions such as Mayo Clinic and MD Anderson Cancer Center with a passion for effective communication and collaboration. With expertise spanning head and neck, lung, cervical, and AML cancers, Vaishnavi excels in delivering compelling scientific presentations to diverse audiences, showcasing outstanding verbal and written communication skills. Presently, Vaishnavi is an oncology scientist and a medical writer at National Comprehensive Cancer Network (NCCN) and contributes to the development of treatment guidelines for gynecological cancers including cervical, uterine and vulvar cancers. My role involves the careful crafting of content that extends beyond guidelines to encompass various educational materials, conference reports, and impactful journal publications. I am committed to maintaining the highest standards of accuracy and relevance in the ever-evolving landscape of oncology. With a keen eye for detail, I ensure that the NCCN Guidelines for Uterine Neoplasms, version 2.2024, reflect the latest advancements in the field, contributing to the enhancement of patient outcomes and the overall quality of care. In the past, as a Scientific Team Lead at Champions Oncology, Vaishnavi spearheaded groundbreaking initiatives, leading a team in establishing tumor-specific organoid models and developing a living organoid biobank. Her strategic vision and ability to foster long-term relationships resulted in successful collaborations with key opinion leaders, biotech entities, and academic partners. Vaishnavi's career also includes pivotal roles such as Scientist II at Champions Oncology, where she identified new business opportunities, completed over 20 preclinical oncology studies, and enhanced departmental productivity through critical decision-making processes. Her experience extends to the initiation and execution of high-impact research projects, such as the discovery of NOTCH1 as a biomarker for head and neck cancer, leading to a phase 2 clinical trial and a US Patent application. With a Ph.D. in Biology from Temple University and a B.Tech in Industrial Biotechnology, Vaishnavi's contributions to scientific literature are noteworthy, with publications in Clinical Cancer Research and Cancer Research, among others. Recognized for her excellence in oncology, she received honorable mentions in "Oncology Times" and AACR Scholar-in-training Awards. Vaishnavi Sambandam is a dynamic and results-driven professional, bringing a unique blend of scientific expertise, project management proficiency, and a proven track record of successful collaboration in the medical and oncology research landscape. AREAS OF EXPERTISE Oncology Tumoroids Organoids Lung Cancer Cervical Cancer Ovarian Cancer Drug Development Targeted Therapeutics Biomarkers

Subject Matter Expertise

• ☆ Molecular Biology
• ☆ Biomarkers
• ☆ DNA Damage & Repair
• ☆ Cell Biology
• ☆ Cell Culture
• ☆ 3D Cell Culture
• ☆ Women's Health
• ☆ Ovarian Cancer
• ☆ Obstetrics & Gynecology
• ☆ Oncology
• ☆ Chemotherapy
• ☆ Cancer Research
• ☆ Cancer Biology
• ☆ Carcinogenesis

Services

• Writing

Writing Medical Writing

Work Experience

Oncology Scientist

National Comprehensive Cancer Network

February 2024 - Present

Scientific Team Lead

Champions Oncology (United States)

April 2021 - September 2023

Research fellow

Mayo Clinic Research in Florida

February 2019 - March 2021

Post Doctoral Fellow

University of Texas MD Anderson Cancer Center

September 2014 - January 2019

Education

PhD in Biology

Temple University

August 2010 - July 2014

Certifications

• Certificate of Completion - Good Clinical Practice

  NIDA Clinical Trials Network

  October 2023 - December 2024

• How to be more strategic in six steps

  LinkedIn

  October 2023 - January 2024

• How to make Strategic Thinking a Habit

  LinkedIn

  July 2023 - January 2024

Publications

JOURNAL ARTICLE

Vaishnavi Sambandam, Mitchell J Frederick, Li Shen, Pan Tong, Xiayu Rao, Shaohua Peng, Ratnakar Singh, Tuhina Mazumdar, Chenfei Huang, Qiuli Li, et al.(2019). PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K/mTOR inhibition . Clinical Cancer Research. p. clincanres.3276.2018. American Association for Cancer Research ({AACR})

G G Jinesh, V Sambandam, S Vijayaraghavan, K Balaji, S Mukherjee(2017). Molecular genetics and cellular events of K-Ras-driven tumorigenesis . Oncogene. 37. (7). p. 839--846. Springer Nature

Nene N. Kalu, Tuhina Mazumdar, Shaohua Peng, Li Shen, Vaishnavi Sambandam, Xiayu Rao, Yuanxin Xi, Lerong Li, Yuan Qi, Frederico O. Gleber-Netto, et al.(2017). Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines . Oncotarget. 8. (49). Impact Journals, {LLC}

Ming Zhang, Ratnakar Singh, Shaohua Peng, Tuhina Mazumdar, Vaishnavi Sambandam, Li Shen, Pan Tong, Lerong Li, Nene N. Kalu, Curtis R. Pickering, et al.(2017). Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors . Cancer Letters. 392. p. 71--82. Elsevier {BV}

Faye M. Johnson, Vaishnavi Sambandam, Li Shen, Ming Zhang, Rishi Saigal, Pan Tong, Tuhina Mazumdar, Lauren A. Byers, Curtis Pickering, Jeffrey N. Myers, et al.(2016). Abstract 393: NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in head and neck squamous cell carcinoma . Cancer Research. 76. (14 Supplement). p. 393--393. American Association for Cancer Research ({AACR})

Ming Zhang, Shaohua Peng, Tuhina Mazumdar, Vaishnavi Sambandam, Li Shen, Pan Tong, Lerong Li, Lauren Byers, Curtis Pickering, Mitchell Frederick, et al.(2016). Abstract 4757: Identification of biomarkers that predict response of head and neck squamous cell carcinoma to mitotic inhibitors . Cancer Research. 76. (14 Supplement). p. 4757--4757. American Association for Cancer Research ({AACR})

Ming Zhang, Tuhina Mazumdar, Shaohua Peng, Pan Tong, Vaishnavi Sambandam, Lauren A. Byers, Jeffrey N. Myers, Jing Wang, Faye M. Johnson(2015). Abstract 2427: The difference of drug sensitivity between HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines: . Cancer Research. 75. (15 Supplement). p. 2427--2427. American Association for Cancer Research ({AACR})

Vaishnavi Sambandam, Li Shen, Ming Zhang, Rishi Saigal, Lauren A. Byers, Curtis Pickering, Jeffrey N. Myers, Jing Wang, Faye M. Johnson(2015). Abstract 417: Integrative drug sensitivity analysis of PI3K /mTOR pathway inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC) . Cancer Research. 75. (15 Supplement). p. 417--417. American Association for Cancer Research ({AACR})

A. Arzumanyan, V. Sambandam, M. M. Clayton, S. S. Choi, G. Xie, A. M. Diehl, D.-Y. Yu, M. A. Feitelson(2012). Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein . Cancer Research. 72. (22). p. 5912--5920. American Association for Cancer Research ({AACR})

Suganya Selvaraj, Vaishnavi Sambandam, Dipasri Sardar, Sharmila Anishetty(2012). In silico analysis of DosR regulon proteins of Mycobacterium tuberculosis . Gene. 506. (1). p. 233--241. Elsevier {BV}